Clinical advice papers for Upadacitinib (RINVOQ®) and decision paper for secukinumab

OIA response


Request for information: 


Thank you for your request dated 03 July 2023 under the Official Information Act 1982 (OIA) for information relating to upadacitinib and secukinumab. You requested:



  1. Clinician Advice Paper


Can I please request the PTAC (19 May 2022 meeting) and the Rheumatology Specialist advisory Committee (28 March 2023) clinical advice papers for the following proposals: 

Upadacitinib (RINVOQ®)(external link)

Psoriatic arthritis (PsA), 3rd line biologic

Seeking Clinical Advice


Upadacitinib (RINVOQ®)(external link)

Psoriatic arthritis, 2nd line biologic

Seeking Clinical Advice



These will be the papers that were written by Pharmac staff to these Committees, seeking their advice. 

  1. Decision Paper 

Can I please request the decision paper to list secukinumab in front line Psoriatic arthritis. 

Secukinumab(external link)

Psoriatic arthritis, 1st biologic line


Novartis, Clinician

Please note that we approach our assessment of requests for information under the OIA on the basis that once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).

We have redacted a small amount of information from the documents as we consider this is necessary to:

  • protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
  • protect information which is subject to an obligation of confidence or which any person has been or could be compelled to provide under the authority of any enactment, where the making available of the information would be likely to prejudice the supply of similar information, or information from the same source, and it is in the public interest that such information should continue to be supplied (section 9(2)(ba)(i));
  • enable Pharmac to carry on, without prejudice or disadvantage, negotiations, including commercial negotiations (section 9(2)(j)).

We trust that this information answers your queries. Please note, you have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.

To make information more freely available, we publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.